Insider Buying: OncoCyte Co. (NASDAQ:OCX) CFO Buys $200,000.05 in Stock

OncoCyte Co. (NASDAQ:OCX) CFO Andrea S. James bought 97,561 shares of OncoCyte stock in a transaction that occurred on Friday, February 7th. The stock was purchased at an average price of $2.05 per share, for a total transaction of $200,000.05. Following the acquisition, the chief financial officer now directly owns 151,231 shares of the company’s stock, valued at $310,023.55. The trade was a 181.78 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

OncoCyte Price Performance

NASDAQ:OCX opened at $2.38 on Friday. The business’s 50-day moving average is $2.20 and its two-hundred day moving average is $2.70. OncoCyte Co. has a 12 month low of $1.92 and a 12 month high of $3.48.

OncoCyte (NASDAQ:OCX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.54). The company had revenue of $0.12 million for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. During the same quarter in the prior year, the firm posted ($0.57) EPS. As a group, equities research analysts predict that OncoCyte Co. will post -2.57 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on OCX. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research note on Wednesday, November 13th. StockNews.com assumed coverage on shares of OncoCyte in a research report on Monday, January 13th. They set a “sell” rating on the stock.

Institutional Trading of OncoCyte

A number of hedge funds have recently made changes to their positions in OCX. FNY Investment Advisers LLC boosted its position in OncoCyte by 15.1% in the 4th quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company’s stock valued at $117,000 after buying an additional 6,481 shares during the last quarter. Geode Capital Management LLC increased its position in shares of OncoCyte by 12.2% during the third quarter. Geode Capital Management LLC now owns 103,980 shares of the company’s stock worth $296,000 after acquiring an additional 11,289 shares during the last quarter. Finally, Pura Vida Investments LLC lifted its stake in shares of OncoCyte by 32.1% in the fourth quarter. Pura Vida Investments LLC now owns 654,451 shares of the company’s stock worth $1,558,000 after acquiring an additional 159,106 shares in the last quarter. Hedge funds and other institutional investors own 55.35% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.